Cargando…
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers
Uterine serous carcinoma (USC) and carcinosarcomas (CSs) are rare, highly aggressive variants of endometrial cancer. No reliable tumor biomarkers are currently available to guide response to treatment or detection of early recurrence in USC/CS patients. Circulating tumor DNA (ctDNA) identified using...
Autores principales: | Bellone, Stefania, McNamara, Blair, Mutlu, Levent, Demirkiran, Cem, Hartwich, Tobias Max Philipp, Harold, Justin, Yang-Hartwich, Yang, Siegel, Eric R., Santin, Alessandro D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10219151/ https://www.ncbi.nlm.nih.gov/pubmed/37240216 http://dx.doi.org/10.3390/ijms24108873 |
Ejemplares similares
-
Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023) -
HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023) -
Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023) -
Improved survival of patients with hypermutation in uterine serous carcinoma
por: Santin, Alessandro D., et al.
Publicado: (2015) -
Which is worse: uterine papillary serous carcinomas or carcinosarcomas?
por: Song, Taejong, et al.
Publicado: (2011)